IPP Bureau
Intracin Pharma secures APVMA nod to supply veterinary medicines in Australia
By IPP Bureau - June 03, 2026
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
Abbott highlights prognostic value of MRD testing for breast cancer recurrence
By IPP Bureau - June 03, 2026
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350
By IPP Bureau - June 03, 2026
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
Cipla appoints Taher Karampurwala as Senior Director and Head of Middle East Business
By IPP Bureau - June 03, 2026
Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region
CARE Hospitals strengthens advanced cardiac care
By IPP Bureau - June 03, 2026
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
Johnson & Johnson brings India’s first PFA technology for atrial fibrillation treatment
By IPP Bureau - June 03, 2026
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
Akums secures European CEP approval for Cefpodoxime Proxetil
By IPP Bureau - June 03, 2026
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
FICCI and Lilly launch Bharat Life Sciences Awards to recognise India’s scientific excellence
By IPP Bureau - June 03, 2026
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
Eurofragance and MartiDerm launch free skincare line to tackle 'fish odor syndrome'
By IPP Bureau - June 03, 2026
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care
By IPP Bureau - June 03, 2026
The filing is backed by Phase III data from the lidERA Breast Cancer study
Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types
By IPP Bureau - June 03, 2026
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
Lupin and Natco get FDA approval for Eribulin Mesylate injection
By IPP Bureau - June 03, 2026
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
Servier to acquire Edgewise muscular dystrophy business in $2.65 billion deal
By IPP Bureau - June 03, 2026
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
Cipla launches India's first sputum inflammometry lab in Mumbai
By IPP Bureau - June 03, 2026
The facility sets a new benchmark in respiratory diagnostics
